Acute Coronary Syndromes Clinical Trial
Official title:
Randomised, Double-blind, Placebo-controlled Trial of IVabradine in Patients With Acute Coronary Syndrome: Effects of the If Current Inhibitor Ivabradine or rEduction of Inflammation maRkers in Patients With Acute Coronary Syndrome
The purpose of this study is to investigate whether a pure heart rate-lowering agent (Ivabradine) reduces vascular inflammatory stress in patients with acute coronary syndromes
The activation of inflammatory pathways plays an important contributory role in coronary plaque instability and subsequent rupture, which can lead to the development of acute coronary syndromes. Elevated levels of serum inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP) represent independent risk factors for further cardiovascular events. Raised resting heart rate (HR) has been shown to be associated with cardiovascular events. Ivabradine is a new HR-reducing agent, which has demonstrated antianginal and anti-ischemic properties in patients with stable angina. In an atherosclerosis model, selective HR reduction with ivabradine has been shown to decrease markers of vascular oxidative stress, to improve endothelial function, and to reduce atherosclerotic plaque formation. We hypothesized that the addition of ivabradine to standard medical therapy has a beneficial effect on markers of inflammatory stress in acute coronary syndrome patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02552407 -
Thrombectomy in ST Elevation Myocardial Infarction, an Individual Patient Meta-analysis
|
N/A | |
| Completed |
NCT01398228 -
Clinical Pathways for the Management of Acute Coronary Syndromes - Phase 3,CPACS-3
|
N/A | |
| Completed |
NCT01135667 -
Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI
|
Phase 4 | |
| Recruiting |
NCT02592720 -
Cocktail Injection Improves Outcomes of FFR Guided PCI
|
Phase 4 | |
| Completed |
NCT01641510 -
PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants
|
Phase 3 | |
| Completed |
NCT01743274 -
Does Optical Coherence Tomography Optimise Results of Stenting
|
N/A | |
| Active, not recruiting |
NCT01433627 -
Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX
|
Phase 3 | |
| Completed |
NCT01452282 -
Ankle-Brachial Index Estimating Cardiac Complications After Surgery
|
N/A | |
| Recruiting |
NCT01418794 -
Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease
|
Phase 4 | |
| Recruiting |
NCT01000701 -
Inflammation and Acute Coronary Syndromes
|
N/A | |
| Terminated |
NCT01107899 -
Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes
|
Phase 1 | |
| Completed |
NCT00494247 -
Endothelial Progenitor Cells-capture Stents in Acute Coronary Syndromes
|
Phase 4 | |
| Terminated |
NCT00615719 -
Computed Tomographic Coronary Angiography for Acute Chest Pain Evaluation
|
N/A | |
| Active, not recruiting |
NCT06089343 -
High-risk Features of Coronary Lesions in CTA and OCT
|
||
| Not yet recruiting |
NCT04023630 -
DUAL Antithrombotic Therapy in Patients With AF and ACS
|
Phase 4 | |
| Recruiting |
NCT02601404 -
REal World Advanced Experience of BioResorbable ScaffolD by SMart Angioplasty Research Team (SMART REWARD)
|
N/A | |
| Completed |
NCT02195193 -
Integrating Depression Care in Acute Coronary Syndromes Care in China
|
N/A | |
| Completed |
NCT02141750 -
THIRD NATIONAL REGISTRY OF ACUTE CORONARY SYNDROMES
|
N/A | |
| Not yet recruiting |
NCT01735227 -
Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN)
|
Phase 4 | |
| Completed |
NCT00097591 -
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
|
Phase 3 |